Saxenda

liraglutide
GLP-1 Receptor Agonist Novo Nordisk FDA Monitored

Safety Profile Overview

Higher-dose liraglutide for chronic weight management. Boxed warning for thyroid C-cell tumors. Distinct from Victoza's diabetes indication.

Generic Name
liraglutide
Brand Names
Saxenda
Therapeutic Class
GLP-1 Receptor Agonist
Manufacturer
Novo Nordisk

What Pharma Signal Tracks for Saxenda

Data Disclaimer: Pharma Signal aggregates data from the FDA Adverse Event Reporting System (FAERS) and other public regulatory sources. FAERS reports do not establish causation. Report counts may reflect prescription volume rather than relative safety. Always consult healthcare professionals for medical decisions.

Get Saxenda Safety Data via API

One API call returns adverse events, risk scores, recalls, and pharmacovigilance signals for Saxenda.

curl "https://api.pharma-signal.com/drug/safety/saxenda" \
  -H "X-API-Key: your_key"

# Returns risk score, adverse event counts,
# serious/death rates, recalls, and signals

Related Safety Intelligence

Pharma Signal provides comparative analysis across therapeutic classes. Compare Saxenda against other GLP-1 Receptor Agonist drugs, or explore the full manufacturer portfolio for Novo Nordisk.